Cordycepin for low CD8+ cells in solid tumor patients
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a supplement derived from cordyceps mushrooms to see if it can raise low CD8+ immune cell levels in people who have had solid tumors. It may help strengthen your immune system after previous cancer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor cancer that was diagnosed by a biopsy or your medical history.
- Your most recent radiation or chemo finished at least 6 months ago.
- A blood test showed your CD8+ cells are below the normal range.
- You have not taken any immune-modifying drugs in the last 2 weeks.
- You are able to do daily activities with little or no help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called PRaG-1 that helps your immune system fight cancer. It is for people with advanced cancer who are generally healthy and do not have serious heart or immune problems.
This trial tests a new way to combine two types of radiation therapy (called PRaG-1 and PRaG) for people with advanced solid tumors that have few treatment options. The goal is to see if this approach can help your immune system fight the cancer better.
This trial tests whether a combination of high-dose vitamin C and cordyceps (a type of fungus used in traditional medicine) can improve quality of life for people with late-stage pancreatic cancer that has progressed after two prior treatments. It looks at how these supplements affect your well-being and daily living.
This trial tests whether adding vitamin C and a fungus called cordyceps to standard chemotherapy can help improve anemia (low red blood cells) in people with advanced pancreatic cancer. It's for those who have not yet had treatment for their cancer.
This trial tests a new type of immune cell therapy (dendritic cells) that is designed to target specific proteins found on cancer cells. It is for people with certain solid tumors who have already had surgery and at least 4 cycles of standard chemotherapy after surgery.
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Hear when a new Lymphopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.